Recombinant C1-Inhibitor

[1]  J. Stockman.  Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2012 .

[2]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[3]  A. Bygum,et al.  Hereditary angio‐oedema in Denmark: a nationwide survey , 2009, The British journal of dermatology.

[4]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[5]  V. Gurewich,et al.  Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis , 2009, Thrombosis and Haemostasis.

[6]  A. Bellatorre,et al.  Plasma biomarkers of acute attacks in patients with angioedema due to C1‐inhibitor deficiency , 2009, Allergy.

[7]  B. Zuraw.  Clinical practice. Hereditary angioedema. , 2008, The New England journal of medicine.

[8]  B. Zuraw.  Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  M. Cicardi,et al.  The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema , 2007, Expert opinion on pharmacotherapy.

[10]  J. C. Rau,et al.  Serpins in thrombosis, hemostasis and fibrinolysis , 2007, Journal of thrombosis and haemostasis : JTH.

[11]  H. Farkas,et al.  Recombinant human C1‐inhibitor in the treatment of acute angioedema attacks , 2007, Transfusion.

[12]  V. Gurewich,et al.  C1‐inhibitor prevents non‐specific plasminogen activation by a prourokinase mutant without impeding fibrin‐specific fibrinolysis , 2007, Journal of thrombosis and haemostasis : JTH.

[13]  D. Shefet,et al.  Arzneimittelkommission der deutschen Ärzteschaft , 2006 .

[14]  A. Eerenberg,et al.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[15]  M. Cicardi,et al.  Bradykinin-mediated angioedema. , 2002, The New England journal of medicine.

[16]  J. Abrahams,et al.  Structural and functional aspects of C1-inhibitor. , 2002, Immunobiology.

[17]  S. Petersen,et al.  Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium: Dose-Related Beneficial Versus Detrimental Effects , 2001, Circulation.

[18]  W. Tremaine,et al.  Hereditary angioedema: a broad review for clinicians. , 2001, Archives of internal medicine.

[19]  C. Hack,et al.  In vitro interaction of C1-inhibitor with thrombin , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  P. Patston,et al.  The inhibition of TNK-t-PA by C1-inhibitor , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  Huijbregts,et al.  Characterization of Recombinant C 1 Inhibitor P 1 Variants * , 2001 .

[22]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[23]  C. Hack,et al.  C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. , 2000, Pharmacological reviews.

[24]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[25]  P. Mannucci,et al.  Activation of the coagulation cascade in C1-inhibitor deficiencies. , 1997, Blood.

[26]  C. Hack,et al.  Modulation of Contact System Proteases by Glycosaminoglycans , 1996, The Journal of Biological Chemistry.

[27]  C. Hack,et al.  Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. , 1995, Blood.

[28]  A. Eerenberg,et al.  Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.

[29]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[30]  C. Hack,et al.  Characterization of recombinant C1 inhibitor P1 variants. , 1992, The Journal of biological chemistry.

[31]  S. Pizzo,et al.  The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). , 1991, Journal of Biological Chemistry.

[32]  R. Huber,et al.  Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. , 1986, Biochemistry.

[33]  R. Colman,et al.  The regulation of human factor XIIa by plasma proteinase inhibitors. , 1985, The Journal of biological chemistry.

[34]  F van der Graaf,et al.  Inactivation of kallikrein in human plasma. , 1983, The Journal of clinical investigation.

[35]  R. Colman,et al.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. , 1982, The Journal of clinical investigation.

[36]  B. Wiman,et al.  On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin. , 1978, European journal of biochemistry.

[37]  H. Movat,et al.  The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors. , 1977, Biochemical and biophysical research communications.

[38]  J. Atkinson,et al.  Hereditary angioedema: the clinical syndrome and its management. , 1976, Annals of internal medicine.